<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Skin autografting</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Skin autografting</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Skin autografting</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jorge Leon-Villapalos, MD, FRCS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Dziewulski, MD, FRCS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc G Jeschke, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy S Colwell, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H713392042"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The routine use of skin grafting, skin substitutes, and tissue flaps with or without skin grafting has dramatically broadened the ability of the surgeon to perform reconstructive surgery and improve outcomes and quality of life for trauma patients, burn patients, and cancer patients. </p><p>A split-thickness graft is composed of epidermis and a variable amount of dermis. A full-thickness graft includes all the layers of the skin. The survivability of a skin graft depends entirely on the blood supply of the recipient wound bed. A number of patient-related factors may influence graft take (eg, comorbidities, nutritional status).</p><p>This topic provides an overview of the use of skin grafts in reconstructive surgery. The use of tissue flaps is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/114188.html" rel="external">"Overview of flaps for soft tissue reconstruction"</a>.)</p><p class="headingAnchor" id="H470953452"><span class="h1">SKIN ANATOMY</span><span class="headingEndMark"> — </span>The skin, which is the largest organ of the body, is responsible for physical protection, homeostasis, temperature control, and immunologic surveillance. It provides an envelope for the subcutaneous tissue, connective tissue, and deep structures and serves as an attachment site (eg, fascia). It is also the ultimate representation of cosmetic appearance, beauty, and aging. The skin is composed of an outer expendable layer of epidermis  (<a class="graphic graphic_figure graphicRef54157" href="/z/d/graphic/54157.html" rel="external">figure 1</a>), which is in continuous regeneration, and an inner layer of dermis responsible for elasticity, pliability, and neurovascular supply of the skin. </p><p class="bulletIndent1"><span class="glyph">●</span>The epidermis is subdivided into five sublayers or strata: basale, spinosum, granulosum, lucidum, and corneum. The cellular content is substituted by keratin nearly completely in the uppermost stratum of corneum. The basal layer separates epidermis and dermis. The dermoepidermal junction is the area of the skin where pigmentation cellular components are located. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The dermis is subdivided into an outer layer called the papillary dermis (separated from the epidermis by the dermoepidermal junction) and an inner layer called the reticular dermis that neighbors the subcutaneous tissue. The dermis is composed of cells, fibers, and a ground substance. The epidermal appendages are subdermal epithelial structures that include sebaceous glands, sweat glands, and hair follicles. The skin is supplied by vascular plexuses from deep-source perforating vessels. </p><p></p><p class="headingAnchor" id="H1129750648"><span class="h1">AUTOGRAFTS</span><span class="headingEndMark"> — </span>An autograft is the transfer of skin from a donor site to a recipient site in the same individual. These are the most used grafts for skin reconstruction for a variety of indications. Autografts can be harvested as split thickness or full thickness. </p><p class="bulletIndent1"><span class="glyph">●</span>Split-thickness skin grafts (STSGs), also called partial-thickness grafts, transfer a portion of the donor site skin, including the epidermis and some of the underlying dermis. This allows the donor site to heal from the epidermal elements left behind, provided that appropriate dermal structures remain viable. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Full-thickness skin grafts (FTSGs) harvest the entire layer of skin as the graft. Thus, no dermal or epidermal elements remain at the donor site, which must be closed by local advancement of the adjoining skin, by a secondary local flap, or by using an STSG. </p><p></p><p>The transplanted skin does not have a blood supply and initially survives by absorbing transudate from the recipient site, a process called plasmatic imbibition [<a href="#rid1">1</a>]. Neovascularization from the graft bed capillaries then provides a blood supply to the graft over the next 48 to 72 hours. Traditional teaching is that STSGs are mainly vascularized from the wound bed while FTSGs are vascularized from the wound edge. The process of revascularization takes longer for an FTSG than for an STSG because of the increased thickness of the tissue. Full circulation is restored within four to seven days. </p><p>The advantages and disadvantages of STSGs and FTSGs are summarized here and described in more detail below. (See <a class="local">'Split-thickness skin grafting'</a> below and <a class="local">'Full-thickness skin grafting'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Split thickness: Good for large areas of coverage, donor sites can be reharvested, fragile, prone to contracture. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Full thickness: Smooth texture and pliability, thicker coverage, reduced take, poor drainage of accumulating fluid. Limited choice of harvesting sites due to need primarily of the donor site.</p><p></p><p class="headingAnchor" id="H894781603"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H632143838"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Indications for skin autografting include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Skin grafts are indicated for the coverage of a skin defect due to burns, trauma, infection, or following excision of a tumor if primary closure cannot be accomplished. (See  <a class="medical medical_review" href="/z/d/html/6319.html" rel="external">"Skin laceration repair with sutures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin grafts can also be used to cover and promote healing of chronic wounds provided the bed of the wound is well prepared and vascularized. (See  <a class="medical medical_review" href="/z/d/html/99040.html" rel="external">"Overview of treatment of chronic wounds", section on 'Wound coverage/closure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin grafts may also be used as an adjunct to tissue flap reconstructive techniques. (See  <a class="medical medical_review" href="/z/d/html/114188.html" rel="external">"Overview of flaps for soft tissue reconstruction", section on 'Skin'</a>.)</p><p></p><p class="headingAnchor" id="H1737511960"><span class="h2">Choice of coverage</span><span class="headingEndMark"> — </span>Whether to use a skin graft versus a tissue flap depends upon the condition and requirement of the recipient bed. A skin graft depends on the vascularity of the recipient site. A well-vascularized bed can accept a graft while a devascularized bed (eg, cartilage or bone) requires flap coverage. In addition, size, location, and aesthetics often dictate the choice. Initially, a skin graft is erythematous and irregular, but over time as the graft matures (three to six months), the graft will smooth out but will retain the color and consistency of the donor site, which is a major shortcoming of a skin graft. A local flap will provide a better aesthetic result than a graft because it allows replacement of "like with like." Moreover, when large defects need to be filled or structures recreated, a flap will be required. (See  <a class="medical medical_review" href="/z/d/html/114188.html" rel="external">"Overview of flaps for soft tissue reconstruction"</a>.)</p><p>Whether to choose a split-thickness skin graft (STSG) or full-thickness skin graft (FTSG) depends upon several factors. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>The size of the defect to cover</p><p class="bulletIndent1"><span class="glyph">●</span>The anatomic area to reconstruct</p><p class="bulletIndent1"><span class="glyph">●</span>The availability of donor sites</p><p></p><p>It is important to take into account the anticipated scar contraction [<a href="#rid2">2</a>]. In general, the degree of contraction is less the thicker the skin graft. Minimal wound contraction occurs with FTSGs. However, with a thicker graft, better vascularity is required [<a href="#rid3">3</a>]. FTSGs are generally reserved for reconstruction of areas of special anatomic and functional importance that require a more pliable reconstruction than can be offered by STSGs. Such areas include cosmetically sensitive areas like the head, eyelids, perioral areas, and neck, and functional areas like the hands. </p><p>Examples for choosing between split thickness and full thickness grafts include: </p><p class="bulletIndent1"><span class="glyph">●</span>For a chronic ulcer, a thinner graft will have decreased metabolic needs, and an STSG is often chosen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients requiring grafts on the face, a FTSG is preferred because of the aesthetic benefits of minimal contraction, as well as better color match and contour.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with large skin defects of the trunk or extremities away from joints, STSGs are preferable because scar contraction will result in a smaller area of scarring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients requiring grafts over areas of mobility (joints) or functionally crucial areas (fingertips), FTSGs are preferable because of the functional benefits of minimal contraction.</p><p></p><p class="headingAnchor" id="H4238490803"><span class="h2">Donor site selection</span><span class="headingEndMark"> — </span>The donor site is selected to minimize discomfort and cosmetic issues while maximizing the outcome at the recipient site, which depends on the desired color, texture, and thickness of the skin at the recipient site. Donor site selection also depends on the availability of tissue. When large areas of skin coverage are needed, any area of the body may be used as a donor site. The donor site of an STSG will remain hyperpigmented for a number of months before returning to normal. An STSG that is harvested too thick will transform the donor site into a wound that may heal in a delayed fashion and with pathological pigmentation and scarring. </p><p>The quality of the donor site skin should also be evaluated for evidence of prior sun damage (eg, keratoses) and prior scarring. </p><p class="bulletIndent1"><span class="glyph">●</span>On the face, it is desirable to replace "like with like" and use skin as close to the recipient site as possible. As an example, nasal tip grafts are often best taken from the preauricular skin rather than the supracervical skin as the color and thickness match are better.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An open wound of the trunk can be grafted from almost any donor site as the skin color and texture are not as important. The upper lateral thigh is a good choice for skin grafting an area on the trunk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>STSGs from the scalp can be used for resurfacing the face and to improve the color match of the skin paddle for patients previously treated with a free flap [<a href="#rid4">4</a>]. </p><p></p><p>Donor sites for FTSGs are from areas of redundant and pliable skin that can be harvested and closed without tension like the groin, medial arm, supraclavicular area, pre- and post-auricular area, and abdomen [<a href="#rid5">5,6</a>]. </p><p class="headingAnchor" id="H3918642670"><span class="h2">Recipient site preparation</span><span class="headingEndMark"> — </span>Proper recipient site preparation is important for both STSGs and FTSGs. The wound bed must be well vascularized and free of all necrotic or ischemic tissue, and without inflammation or infection. </p><p>Surgically created wounds are designed to leave a well-vascularized bed, so no special preparation is required. Similarly, once injured and devascularized tissue is removed, acute traumatic wounds often have a healthy bed. </p><p>Chronic wounds may take a period of dressing changes to promote neovascularization in the bed. (See  <a class="medical medical_review" href="/z/d/html/99040.html" rel="external">"Overview of treatment of chronic wounds", section on 'Wound bed preparation'</a>.)</p><p>Granulation tissue can be heavily colonized, and, at the time of skin grafting, it should be gently debrided back to the wound base. Skin margins should be trimmed to expose healthy, unscarred dermis. Hemostasis must be meticulous to prevent blood or fluid collections from accumulating beneath the graft because these are a common cause of graft failure [<a href="#rid7">7</a>]. If the base is bony or tendinous, a graft may not take. The recipient site should also be thoroughly irrigated prior to graft placement. </p><p class="headingAnchor" id="H3764623101"><span class="h2">Minimizing blood loss</span></p><p class="headingAnchor" id="H3363149021"><span class="h3">Tumescent infiltration</span><span class="headingEndMark"> — </span>Tumescent infiltration with large diluted volumes of local anesthesia (eg, <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> 2 to 3 mg/kg maximum dose with <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>) or vasoconstricting agents (1 mL of 1:1000 adrenaline per 1000 mL) in normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> reduces intraoperative blood loss and postoperative pain [<a href="#rid8">8-11</a>]. Various techniques are used, and the devices used for injecting tumescent infiltration into the skin vary from simple syringes and needles for small areas to powerful mechanically assisted devices that deliver large volumes of infiltration through large, wide needles. Our standard infiltration of both burned tissue and donor sites is one liter of normal saline with an ampule of 1:1000 epinephrine. For local anesthesia, we use a mixture of 1% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> and bupivacaine 0.25%. The bupivacaine provides longer duration analgesia for donor site pain as these areas are the most problematic for postoperative pain control. </p><p>Tumescent infiltration to facilitate graft harvesting can reduce intraoperative blood loss and postoperative pain, particularly in the setting of burn surgery [<a href="#rid8">8-10,12</a>]. In a nonrandomized study, tumescent infiltration of the donor and burn sites with subdermal injections of diluted <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> resulted in a significant reduction of intraoperative blood loss compared with a similar group of burn patients not treated with these techniques [<a href="#rid12">12</a>]. </p><p class="headingAnchor" id="H995236113"><span class="h3">Other methods</span><span class="headingEndMark"> — </span>Other methods for reducing blood loss during split-thickness skin grafting include direct pressure, the use of topical hemostatic agents  (<a class="graphic graphic_table graphicRef71852" href="/z/d/graphic/71852.html" rel="external">table 1</a>), electrosurgical devices for wound bed hemostasis, and <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a>. Topical hemostatic agents and electrocautery devices are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15069.html" rel="external">"Overview of topical hemostatic agents and tissue adhesives"</a> and  <a class="medical medical_review" href="/z/d/html/7938.html" rel="external">"Fibrin sealants"</a> and  <a class="medical medical_review" href="/z/d/html/2890.html" rel="external">"Overview of electrosurgery"</a>.)</p><p>Systemic <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> (TXA) has been used to minimize blood loss in other types of surgery (eg, hip arthroplasty, scoliosis surgery) and may also to be effective for burn excision [<a href="#rid13">13</a>]. A handful of observational studies have reported reductions in blood loss transfusion and fluid requirement for burn patients receiving TXA [<a href="#rid13">13-15</a>]. In a small randomized trial, 30 patients with burns (&lt;30 percent TBSA) were randomly assigned to a single dose of intravenous tranexamic acid (15 mg/kg) or placebo (10 mL <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) [<a href="#rid16">16</a>]. The average blood loss per cm<sup>2</sup> burn area excised was significantly lower for those who received TXA compared with the placebo group (0.45 versus 0.73 mL/cm<sup>2</sup>; mean difference 0.28 ± 0.025 mL/cm<sup>2</sup>, 95% CI 0.23-0.33). The total volume of blood loss was also lower in TXA group but was not statistically significant (258.7 versus 388.1 mL). Graft take was similar for both groups (near 100 percent). None of the patients required transfusion, and fluid requirements were similar between the groups. </p><p class="headingAnchor" id="H561992127"><span class="h2">Grafting</span><span class="headingEndMark"> — </span>Techniques by which to accomplish partial-thickness and full-thickness skin autografting are well established and follow an orderly sequence. Allografts and xenografts are placed in a similar manner but without the need to harvest tissue. The steps involved are discussed fully below. (See <a class="local">'Split-thickness skin grafting'</a> below and <a class="local">'Full-thickness skin grafting'</a> below.)</p><p>The application of skin substitutes is similar, also without the need to harvest tissue. (See  <a class="medical medical_review" href="/z/d/html/118064.html" rel="external">"Skin substitutes"</a>.)</p><p class="headingAnchor" id="H1650789753"><span class="h2">Graft take</span><span class="headingEndMark"> — </span>The rate of graft take, or skin graft survival, for STSG (sheet or meshed) is approximately 95 percent. Optimal rates require that the wound is free of infection and that the patient has optimal infection control and nutritional status. The graft take for FTSGs is similar, provided the wound is appropriately and freshly debrided, the patient's physiology and ability to heal is unaffected, and there are no microbiology concerns. When there is less-than-optimal debridement, infection, or deranged physiology, graft take will be compromised. </p><p>The local and systemic factors that decrease the survival of skin grafts are similar for STSGs and FTSGs. The main factor that reduces graft take and survival for skin grafts is a lack of initial adhesion to the recipient site due to the presence of a hematoma or seroma that inhibits revascularization. For FTSGs, small perforations may not be sufficient to drain any accumulating fluid. Other local factors that are associated with decreased skin graft survival include inadequate vascularity, such as the presence of unvascularized bone or tendon or local tissue hypoxia from underlying vascular disease, prior irradiation or smoking, excess mobility, and placement in an area of high contact or friction (eg, back, anorectal area). </p><p>Systemic factors that may decrease the survival of STSGs include older age, malnutrition, medical comorbidities, and pharmacologic therapies known to affect wound healing (eg, glucocorticoids), among others. (See  <a class="medical medical_review" href="/z/d/html/112216.html" rel="external">"Risk factors for impaired wound healing and wound complications"</a>.)</p><p class="headingAnchor" id="H713392056"><span class="h1">SPLIT-THICKNESS SKIN GRAFTING</span><span class="headingEndMark"> — </span>The split-thickness skin graft (STSG) is the most frequently used donor for tissue coverage. An STSG includes the epidermis and varying amounts of dermis, ranging between 8/1000 of an inch (0.196 millimeters) and 12/1000 of an inch (0.294 millimeters). </p><p class="headingAnchor" id="H2412107750"><span class="h2">Advantages</span><span class="headingEndMark"> — </span>The main advantages of split-thickness skin grafting include the ability to cover large surface areas with less donor skin, and that donor sites may be reharvested once healing is complete (generally in 10 to 15 days). Reharvesting, together with expansion of the graft by meshing techniques, and combination with allograft techniques (sandwich technique: 1:2 autograft covered with 1:4 allograft) allow for coverage of larger defects. A degree of caution needs to be observed in older adults in whom the dermis is thinner; injudicious thick harvesting may lead to difficult-to-heal wounds. </p><p>Prior to reharvesting, the patient's nutritional status must be optimized, and the donor site wound must show evidence of reepithelialization with no evidence of local infection. </p><p class="headingAnchor" id="H50049672"><span class="h2">Disadvantages</span><span class="headingEndMark"> — </span>The disadvantages of STSGs include fragility, abnormal pigmentation, lack of smooth texture, and lack of hair. The lack of a dermal element and, thus, limited pliability and elasticity increase the likelihood of contracture. When used to reconstruct large burns of the face, STSGs may yield an undesirable, mask-like appearance. In addition, the donor site is an additional cause of significant pain. </p><p class="headingAnchor" id="H1440790669"><span class="h2">STSG technique</span><span class="headingEndMark"> — </span>The steps involved during split-thickness skin grafting are described in the sections below. Harvesting can be performed using local anesthesia if the size of the graft harvesting is small. Otherwise, the procedure is performed with additional sedation or under general anesthesia.</p><p>The harvesting area is chosen according to availability. Characteristically, a convex area is chosen for ease of harvesting, such as the lateral and anterior thigh. (See <a class="local">'Donor site selection'</a> above.)</p><p>The area is shaved and marked, and tumescent infiltration with a local anesthetic and/or <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> mixed with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> is performed at the donor and burn wound sites. (See <a class="local">'Tumescent infiltration'</a> above.)</p><p class="headingAnchor" id="H1931461007"><span class="h3">Skin harvest</span><span class="headingEndMark"> — </span>The methods of STSG harvesting have evolved from free-hand with a knife to the use of a handheld dermatome. Either an electrical or compressed air-powered dermatome (authors' choice) can be used [<a href="#rid17">17</a>]. </p><p>The dermatome has a large scalpel-like blade with adjustable depth gauge. Dermatomes are graded in multiples of 1/1000 of an inch and 5/100 of a millimeter, with most grafts harvested between 8/1000 and 12/1000 of an inch. Harvesting thicker grafts requires a longer time for donor sites to heal and may preclude that site from repeat harvesting, which is particularly important in burn patients. </p><p>The harvesting area is layered with liquid paraffin, <a class="drug drug_general" data-topicid="10213" href="/z/d/drug information/10213.html" rel="external">mineral oil</a>, or surgical water-based lubricating gel to reduce friction and facilitate harvesting. The donor site is put on tension by the assistant and the dermatome engaged on the skin surface at an angle of approximately 45 degrees and gently pushed forward while exerting a modest amount of downward pressure on the dermatome. The partial-thickness skin will come off the blade as the dermatome is moved forward. At the completion of the harvest, the dermatome is lifted, which usually severs the graft. If the graft does not come completely off the donor site, a scalpel can be used to complete the final cut. The graft is then transferred to the recipient site, or meshed prior to transfer. (See <a class="local">'Graft meshing'</a> below.)</p><p>Intraoperatively, while the graft is being meshed and inset into the recipient site, hemostasis at the donor site can be achieved using gauze soaked in a solution of one liter normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and one ampule of 1:1000 <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>. Local anesthesia (generally <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> 0.5% with epinephrine) can be infiltrated at the donor site to provide pain relief in the perioperative period. STSG donor sites are subsequently covered with a nonadherent dressing. (See <a class="local">'Donor site dressings and care'</a> below.)</p><p class="headingAnchor" id="H2331169530"><span class="h3">Graft meshing</span><span class="headingEndMark"> — </span>The harvested STSG can be expanded through a meshing device (1:1.5 to 1:9 expansion) to increase its surface area when additional coverage is needed  (<a class="graphic graphic_picture graphicRef77019" href="/z/d/graphic/77019.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef57087" href="/z/d/graphic/57087.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef63714" href="/z/d/graphic/63714.html" rel="external">picture 3</a>). Meshed skin grafts also allow fluid to drain freely from the interstices (ie, openings) of the meshed graft, which improves graft take. The most common ratios for meshing skin grafts include 1:1 mesh (mini mesh), 2:1 mesh, and 4:1 mesh (with overlying 2:1 meshed allograft), depending on the availability of donor sites. </p><p>Larger mesh ratios are reserved for patients with limited donor sites such as patients with severe burns. However, meshed grafts heal with more scarring due to the secondary healing of the interstices and are therefore less aesthetically appealing  (<a class="graphic graphic_picture graphicRef70840" href="/z/d/graphic/70840.html" rel="external">picture 4</a>) compared with sheet (unmeshed) skin grafts. Accordingly, graft meshing is reserved for areas where the aesthetic outcome is of less importance. Unmeshed sheet grafts are used in cosmetically sensitive areas, such as the face and hands [<a href="#rid18">18,19</a>].</p><p>The Meek technique, first described in 1958, is an alternative technique for expanding autografts. It uses a special dermatome and prefolded gauzes to obtain a regular expansion of autograft squares from small pieces of split skin grafts of up to a 1:9 expansion. The Meek techniques can be used on its own or combined with other techniques such as allograft, dermal templates, or cultured keratinocytes both in the adult and pediatric populations [<a href="#rid20">20-23</a>]. In our experience, the ultimate cosmetic appearance of a Meek-covered area is superior to that of other widely meshed techniques.</p><p class="headingAnchor" id="H313456075"><span class="h3">Graft placement and fixation</span><span class="headingEndMark"> — </span>Prior to placement of the skin graft, the wound bed is debrided and must be free of a hematoma, exudate, or infection. (See <a class="local">'Recipient site preparation'</a> above.)</p><p>STSGs are transferred dermis-side-down to the recipient site and fixed into place. The grafts can be secured using staples, sutures, or tissue glue. </p><p>Staples are the fastest method of securing the graft to the wound. The technique is straightforward, and the staples are relatively inexpensive. If the wound has an unusual surface contour, multiple tacking sutures can also be used. Placement of a large number of staples will generally require removal in the operating room and may require general anesthesia. There is also the potential of leaving embedded staples in the wound, which may result in nonhealing wounds, infection, and pain. </p><p>For small skin grafts in sensitive anatomic areas in our practice, we use 4-0 or 5-0 rapidly absorbable suture (eg, 4-0 Vicryl Rapide, 5-0/6-0 Vicryl Rapide for the head and neck). For other small STSGs, tissue adhesives can be used to secure a graft instead of suture [<a href="#rid24">24-26</a>]. Fibrin sealants are used for their hemostatic and adhesive properties [<a href="#rid27">27</a>]. In addition, with less movement of the graft, fewer sutures or staples are needed to secure the graft to the wound bed. Two prospective multicenter trials found a significant decrease in hematomas and seromas and improved viability with the use of fibrin sealants compared with staples in burn wounds [<a href="#rid28">28-30</a>]. For non-burn skin grafting, in one series of 15 patients with 17 lower extremity ulcers, most of the skin grafts (13/17) healed successfully using fibrin glue instead of suture to secure STSGs [<a href="#rid26">26</a>]. There are no trials comparing other types of glue (eg, cyanoacrylates) with suture for fixation of STSGs. The typical concentration used is 4 to 5 units/mL. This reduced concentration does increases the time for the sealant to set, allowing more time to manipulate the graft on the wound [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/15069.html" rel="external">"Overview of topical hemostatic agents and tissue adhesives", section on 'Tissue adhesives and sealants'</a> and  <a class="medical medical_review" href="/z/d/html/7938.html" rel="external">"Fibrin sealants", section on 'Graft or flap adhesion'</a>.)</p><p>Once the STSG is fixed in place, appropriate coverage is necessary to stabilize the skin graft. Recipient site dressings and care are discussed below. (See <a class="local">'Recipient site dressings and care'</a> below.)</p><p class="headingAnchor" id="H2972619160"><span class="h2">Donor site dressings and care</span><span class="headingEndMark"> — </span>The donor site dressing should promote reepithelialization with a minimum amount of pain and discomfort [<a href="#rid32">32</a>]. Since regenerated skin from the donor site may need to be reharvested, meticulous care is warranted for maintaining tissue availability and integrity and to minimize the risk of infection. The donor site is evaluated every 72 hours until healed.</p><p class="headingAnchor" id="H1012348394"><span class="h3">Dressings</span><span class="headingEndMark"> — </span>Several types of dressings are available to manage the donor site wound [<a href="#rid33">33-35</a>]. (See  <a class="medical medical_review" href="/z/d/html/13509.html" rel="external">"Topical agents and dressings for local burn wound care"</a>.)</p><p>The optimal dressing for donor sites continues to be debated, and no one dressing has been proven superior to another. The type used typically depends upon surgeon preference and availability [<a href="#rid32">32,36-38</a>]. A review that included 35 randomized trials and 22 observational studies noted difficulties in making accurate comparisons between moist and nonmoist dressings because of methodological heterogeneity [<a href="#rid36">36</a>]. Although nonmoist adherent dressings may be the most commonly applied dressings to the donor site (eg, bismuth-impregnated petrolatum gauze), there is some weak evidence to support the use of moist dressings, which appear to be associated with less pain and may have lower rates of infection and improved quality of healing. </p><p>In our unit, we place a nonadherent dressing pad (eg, Telfa Clear [polyethylene terephthalate], Mepitel [silicone], or Jelonet [paraffin gauze]) as the contact layer on the donor site, covered with a layer of thick gauze to absorb any fluid and secured with a crêpe wrap bandage, Elastoplast elastic bandage, or Tegaderm adhesive dressing [<a href="#rid39">39,40</a>]. In a pilot study assessing pain and ease of removal of the donor site dressings, Telfa Clear was easier to remove and less painful compared with Jelonet; however, donor sites covered with Jelonet appeared to heal faster [<a href="#rid39">39</a>]. Another small trial compared a film dressing (Mepitel) with traditional gauze dressings at skin graft donor sites [<a href="#rid40">40</a>]. The film dressings had lower pain scores and complication rates compared with gauze dressings. However, there is a tendency for moist dressings to be labor intensive for both the patient and the caregiver. In a randomized trial that included 22 patients, management of the donor site with an absorbent synthetic dressing with properties of natural epithelium (ie, Suprathel) had similar healing times and reepithelialization rates compared with Jelonet [<a href="#rid35">35</a>]. However, there was less pain, less frequent dressing changes, and better attachment to donor site surfaces with Suprathel.</p><p>For donor sites on the back, we use Biobrane as the primary contact dressing, covered with a layer of Jelonet, povidone iodine-soaked gauze, dry gauze, and a securing dressing. Some have noted that attempts at using moist dressings such as Tegaderm and Biobrane improved pain control, but with a higher rate of drainage from the site and need for caregiver intervention prior to healing. </p><p>Hydrocolloid dressings may be associated with the fastest healing rates of the donor site wound following split-thickness harvesting [<a href="#rid32">32,41</a>]. In a randomized trial that included 289 patients with a donor site wound, 49 patients managed with hydrocolloid dressings reepithelialized seven days faster compared with patients managed with other dressings (ie, alginate, film, gauze, hydrofiber, silicone; median 16 versus 23 days) [<a href="#rid32">32</a>]. The risk of infection was higher for patients managed with gauze compared with all other dressings (18.0 versus 7.6 percent, relative risk [RR] 2.38, 95% CI 1.14-4.99). Overall pain scores were low, with the lowest pain score associated with film.</p><p class="headingAnchor" id="H1928383873"><span class="h3">Adjuncts for healing</span><span class="headingEndMark"> — </span>Less common approaches to enhance healing of the donor site wound include overgrafting donor sites [<a href="#rid42">42</a>] extracorporeal shock wave therapy [<a href="#rid43">43</a>] and keratinocyte cell spray [<a href="#rid44">44,45</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Overgrafting donor sites with widely meshed spare skin is particularly useful in older adults where delayed donor site healing can be a problem. While initially described over 30 years ago [<a href="#rid42">42</a>], interest in the technique has increased [<a href="#rid46">46,47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extracorporeal shock wave therapy enhances revascularization and repair of healing soft tissue [<a href="#rid43">43</a>]. In a trial of 28 patients with burns or acute traumatic wounds, the delivery of a single treatment to the donor site immediately after harvesting reduced the time to reepithelialization compared with standard topical therapy (13.9 versus 16.7 days). Time to reepithelialization was defined as the time from skin graft harvest to first documentation of greater than 95 percent reepithelialization. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cell-based therapies (eg, keratinocyte spray) have been used to augment healing in grafted burn wounds and donor sites and have been shown to reduce donor site requirements and improve patient comfort [<a href="#rid48">48,49</a>]. ReCell is a rapid, autologous cell harvesting procedure that enables the cells from an STSG biopsy to be processed into an immediate cell population and is applied as a spray to cover the wound to be treated as well as the biopsy donor site [<a href="#rid44">44</a>]. In a randomized trial of 82 patients with deep partial-thickness burns, patients treated with ReCell had similar aesthetic and functional outcomes compared with patients treated with the conventional STSG [<a href="#rid45">45</a>]. Patients treated with ReCell had significantly less postoperative pain by the visual analogue scale (3.3 versus 6.8) and smaller STSG donor sites (2.2 versus 110 cm<sup>2</sup>). </p><p></p><p class="headingAnchor" id="H713392063"><span class="h1">FULL-THICKNESS SKIN GRAFTING</span><span class="headingEndMark"> — </span>Full-thickness skin grafts (FTSGs) harvest the entire layer of skin as the graft, including the dermal and epidermal elements. Because of the increased thickness of the tissue, revascularization of the donor skin takes longer for an FTSG than for a split-thickness skin graft (STSG).</p><p class="headingAnchor" id="H1676227297"><span class="h2">Advantages</span><span class="headingEndMark"> — </span>FTSGs provide improved texture, pliability, elasticity, aesthetics, and color match and are more resistant to secondary contracture compared with STSGs [<a href="#rid50">50</a>]. FTSGs have an aesthetic advantage when used to cover wounds affecting the face and hands. There is also greater patient satisfaction for both the recipient site and donor site [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H897795454"><span class="h2">Disadvantages</span><span class="headingEndMark"> — </span>The major limitations and disadvantages of using FTSGs include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Limited availability of high-quality donor skin since donor sites lack the ability to self-regenerate. Reharvesting in the same area is limited by the elasticity of surrounding skin. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Not all areas of the body are suitable as donor sites, because an FTSG should ideally match the recipient site for color, skin thickness, and texture. A drawback of applying an FTSG to the face is the potential color mismatch, with results varying from hypopigmentation to hyperpigmentation [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lack of interstices in FTSGs increases the risk for hematoma and seroma formation and may reduce graft take [<a href="#rid52">52</a>]. (See <a class="local">'Graft take'</a> above.)</p><p></p><p class="headingAnchor" id="H451034789"><span class="h2">FTSG technique</span><span class="headingEndMark"> — </span>The steps involved during full-thickness skin grafting are described in the sections below. Harvesting can be performed using local anesthesia if the size of the graft harvesting is small. Otherwise, the procedure is performed with additional sedation or under general anesthesia.</p><p>The harvesting area is chosen according to availability. There is sufficient laxity and pliability of the skin in the supraclavicular and groin regions and the inner upper arm areas to permit mobilization of the surrounding tissues to achieve a primary closure of the donor site. (See <a class="local">'Donor site selection'</a> above.)</p><p>The area is shaved and marked, and tumescent infiltration with a local anesthetic and/or <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> mixed with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> is performed at the donor and burn wound sites. (See <a class="local">'Tumescent infiltration'</a> above.)</p><p>The donor site is closed primarily by local advancement of the adjoining skin by using a secondary local flap or occasionally an STSG (if the donor site is very large). (See <a class="local">'Skin harvest'</a> above.)</p><p class="headingAnchor" id="H851842097"><span class="h3">Skin harvest</span><span class="headingEndMark"> — </span>An FTSG is harvested free-hand using a scalpel, without the use of a dermatome.</p><p>Since an FTSG contracts very little as it heals, the donor skin should be tailored to fit the exact size and shape of the defect. A template of<sup> </sup>the defect should be made using a flexible material (eg, sterile paper or gauze) that can conform to the defect. This allows for a "tailor-made" fit for the harvested skin, without removing more skin than is required. </p><p>Donor site incision should be planned along natural skin creases (relaxed skin tension lines or Langer's lines), particularly in the face  (<a class="graphic graphic_figure graphicRef50913" href="/z/d/graphic/50913.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef57566" href="/z/d/graphic/57566.html" rel="external">figure 3</a>). Violating these lines leads to more visible scars as a result of wound closure. Excess tension in a skin closure can lead to unsightly hypertrophic scarring. </p><p>The incision is made with a scalpel, and sharp dissection of the full thickness of skin is performed. The use of electrocautery during graft harvest should be minimized to minimize thermal injury to the graft. We depilate and remove the subcutaneous adipose tissue from the dermis of the FTSG (ie, defatting), as needed, prior to placing it in the recipient site. This can be accomplished using sharp, fine scissors (eg, McIndoe scissors), holding the graft between the thumb and the index of the nondominant hand on top of a wet gauze swab. </p><p class="headingAnchor" id="H3878494026"><span class="h3">Graft placement and fixation</span><span class="headingEndMark"> — </span>The wound is debrided and must be free of a hematoma, exudate, or infection. (See <a class="local">'Recipient site preparation'</a> above.)</p><p>The FTSG is inset into the recipient site and sutured into place using fine, rapidly absorbable sutures (eg, 4-0 Vicryl Rapide, 5-0/6-0 Vicryl Rapide for the head and neck). Quilting sutures can be used to fix the graft to the recipient site. Small incisions are made to perforate the full thickness to facilitate evacuation of blood exudate without compromising graft integrity.</p><p>Tissue adhesives have also been used for FTSGs [<a href="#rid29">29,53</a>]. (See  <a class="medical medical_review" href="/z/d/html/7938.html" rel="external">"Fibrin sealants", section on 'Graft or flap adhesion'</a>.)</p><p class="headingAnchor" id="H3407628587"><span class="h2">Donor site closure</span><span class="headingEndMark"> — </span>FTSG donor sites are managed by meticulous hemostasis and primary closure with absorbable or nonabsorbable sutures, ensuring there is no tension on the wound. </p><p>Steri-Strips are applied to the suture line, followed by dry gauze secured with a wrap bandage or adhesive dressing.</p><p>The use of skin substitutes (single layer, bilayer) has increased the number of reconstructive options for surgeons. (See  <a class="medical medical_review" href="/z/d/html/118064.html" rel="external">"Skin substitutes"</a>.)</p><p class="headingAnchor" id="H41020275"><span class="h1">RECIPIENT SITE DRESSINGS AND CARE</span><span class="headingEndMark"> — </span>The dressing in contact with the graft recipient site should be nonadherent. In our practice, we prefer to use clear, plastic-based wound dressings that allow inspection of the wound, are atraumatic, and can be covered by a layer of <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">silver nitrate</a> or iodine soaks. After removal of the bandages, the graft will be dry, and a gentle daily application of moisturizer is helpful. </p><p>When Integra is used, we cover it with a double layer of nonadhesive iodine-impregnated dressing as the primary dressing.</p><p class="headingAnchor" id="H4119846301"><span class="h2">Graft immobilization</span><span class="headingEndMark"> — </span>Immobilization of the graft to the recipient bed is imperative to prevent shearing of the graft and/or accumulation of fluid under the graft, which would prevent the process of neovascularization, thus causing skin graft failure. Although meshed STSGs can drain underlying wound fluid through the interstices, the graft still needs to be immobilized to facilitate healing. For FTSGs, immobilization is also crucial as there are no mesh interstices to allow fluid drainage. A bolster dressing  (<a class="graphic graphic_picture graphicRef126546" href="/z/d/graphic/126546.html" rel="external">picture 5</a>) or a negative pressure wound therapy device can be used to ensure immobilization of the healing graft. (See  <a class="medical medical_review" href="/z/d/html/2881.html" rel="external">"Negative pressure wound therapy"</a>.)</p><p>Negative pressure wound therapy  (<a class="graphic graphic_figure graphicRef50588" href="/z/d/graphic/50588.html" rel="external">figure 4</a>) minimizes shearing and subgraft fluid accumulation [<a href="#rid54">54-56</a>]. For large areas, and specifically for those close to joints, we always use negative pressure wound therapy dressings in the immediate post-graft period. It is also our preference for most other areas, when available. The device is usually left in place for 5 to 10 days after graft placement.</p><p>If negative pressure wound therapy is not available, independent of the size of the graft, we use a bolster. Bolster dressings have long been used to cover the graft and hold it in place. Bolstering and tie-over of the grafts may help in protecting the skin grafts, though their usefulness in applying pressure in the interface between recipient and graft area to ensure better take has been questioned [<a href="#rid57">57</a>]. A gauze or cotton bolster is usually applied to absorb the exudate. The bolster dressing can be sewn in place by placing stitches (3-0/4-0 nylon or polypropylene, 5-0/6-0 in the head and neck) around the periphery of the graft and leaving them long enough to tie together over the bolster. </p><p class="headingAnchor" id="H258794083"><span class="h2">Limb immobilization and elevation</span><span class="headingEndMark"> — </span>STSGs that are placed in areas subjected to shear because of motion (eg, axilla, antecubital fossa, or popliteal fossa) also require stabilization with a splint prior to leaving the operating room. Postoperatively, splinting provides for anatomical and functional preservation and minimizes early abnormal scar formation [<a href="#rid58">58,59</a>].</p><p>In addition, extremities that are grafted should be elevated for four to five days to decrease postoperative edema. </p><p class="headingAnchor" id="H2510099148"><span class="h1">POSTOPERATIVE CARE AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Close surveillance of the grafted wound facilitates early detection of graft shearing, hematomas, seromas, or any other problems that may affect graft survival. Thus, we inspect all recipient sites on postoperative day 2 and donor sites at postoperative day 5. For skin substitutes (eg, Matriderm, Integra), we remove the bolster for inspection at three to five days. </p><p>In the early postoperative period, immobilization of the reconstructed grafted wound by limiting physical activity is important to avoid rebleeding, hematoma, or dehiscence until graft inspection. This period of rest allows successful graft adhesion and revascularization. Precautions are maintained until early maturation and donor site healing have occurred, typically at approximately one month post-procedure. </p><p>A fundamental component to postoperative management is mobilization of the patient with the initiation of occupational therapy and/or physical therapy. A careful balance must be achieved between graft protection and preservation of motion in joints. Early mobilization is necessary to preserve function, but excessive early joint mobilization before full graft take or adequate wound healing will shear and destroy grafts by interfering with graft adhesion and compromise the reconstruction. There have been a number of studies [<a href="#rid60">60</a>] showing that early mobilization and ambulation do not adversely affect the take of STSGs in the lower limb and are important in enhanced recovery programs.</p><p class="headingAnchor" id="H3648684072"><span class="h1">COMPLICATIONS</span></p><p class="headingAnchor" id="H632143779"><span class="h2">Graft failure</span><span class="headingEndMark"> — </span>Graft failure can result from insufficient vascularity of the recipient site, hematoma, seroma, infection, excessive tension, or mechanical shearing forces. Proper preparation of the wound bed, meticulous hemostasis, careful inset of the graft, and proper dressing along with immobilization during the healing period can help avoid most of these complications [<a href="#rid1">1</a>]. </p><p>Comorbidities, including diabetes, smoking, and protein or vitamin deficiencies, can affect vascularity and wound healing. In addition, medications such as steroids, immunosuppressive medications, and anticoagulants can interfere with wound healing. These are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/112216.html" rel="external">"Risk factors for impaired wound healing and wound complications"</a>.)</p><p>Infection is most commonly due to methicillin-resistant coagulase-positive staphylococci (MRSA), beta-hemolytic streptococci, or pseudomonas [<a href="#rid1">1</a>]. Cultures should be obtained to direct antibiotic treatment. Partial graft loss can be treated with wet to moist saline-soaked gauze or other local dressings and usually will heal secondarily. Complete graft loss requires reassessment of the bed. When the wound bed is well vascularized, then regrafting can be attempted. </p><p class="headingAnchor" id="H79416050"><span class="h2">Hypertrophic scarring and keloid formation</span><span class="headingEndMark"> — </span>All grafted areas will leave a scar at both the recipient and the donor site. Such a scar can turn into a hypertrophic or keloid scar that may require appropriate management. Preventive measures and treatment of established scars are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5569.html" rel="external">"Keloids and hypertrophic scars"</a> and  <a class="medical medical_review" href="/z/d/html/95111.html" rel="external">"Hypertrophic scarring and keloids following burn injuries", section on 'Preventive strategies and their efficacy'</a>.)</p><p class="headingAnchor" id="H864017684"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117752.html" rel="external">"Society guideline links: Care of the patient with burn injury"</a>.)</p><p class="headingAnchor" id="H1933287"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin autografting</strong> – A skin autograft is defined as a transfer of skin from the donor site to the recipient site without the benefit of any blood supply. The routine use of skin autografts and flaps has dramatically broadened the ability of the surgeon to perform reconstructive surgery and improve outcomes and quality of life for trauma patients, burn patients, and cancer patients. (See <a class="local">'Skin anatomy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Split-thickness skin grafts</strong> – Split-thickness skin grafts (STSGs) transfer a portion of the donor site skin layer including the epidermis and some of the underlying dermis. The use of STSGs and techniques for placement are reviewed above. (See <a class="local">'Split-thickness skin grafting'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Full-thickness skin grafts</strong> – Full-thickness skin grafts (FTSGs) harvest the entire layer of skin as the graft. The use of FTSGs and techniques for placement are reviewed above. (See <a class="local">'Full-thickness skin grafting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wound bed preparation</strong> – Proper preparation of the recipient site is crucial for both STSGs and FTSGs. Prior to grafting any wound bed, the surgeon must make certain that the bed is ready to accept the graft and free from necrotic or ischemic tissue, inflammation, and infection. (See <a class="local">'Recipient site preparation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – The main cause of skin graft failure is graft movement, which interferes with neovascularization and encourages fluid collection under the graft, which can lead to infection and poor revascularization. (See <a class="local">'Graft failure'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ratner D. Skin grafting. Semin Cutan Med Surg 2003; 22:295.</a></li><li><a class="nounderline abstract_t">Ogawa R, Hyakusoku H, Ono S. Useful tips for successful skin grafting. J Nippon Med Sch 2007; 74:386.</a></li><li><a class="nounderline abstract_t">Harrison CA, MacNeil S. The mechanism of skin graft contraction: an update on current research and potential future therapies. Burns 2008; 34:153.</a></li><li><a class="nounderline abstract_t">Lannon DA, Novak CB, Neligan PC. Resurfacing of colour-mismatched free flaps on the face with split-thickness skin grafts from the scalp. J Plast Reconstr Aesthet Surg 2009; 62:1363.</a></li><li><a class="nounderline abstract_t">Celiköz B, Deveci M, Duman H, Nşanci M. Recontruction of facial defects and burn scars using large size freehand full-thickness skin graft from lateral thoracic region. Burns 2001; 27:174.</a></li><li><a class="nounderline abstract_t">Jabaiti SK. Use of lower abdominal full-thickness skin grafts for coverage of large skin defects. European Journal of Scientific Research 2010; 39:134.</a></li><li><a class="nounderline abstract_t">Ratner D. Skin grafting. From here to there. Dermatol Clin 1998; 16:75.</a></li><li><a class="nounderline abstract_t">Mackie IP, Greenwood J. A simple technique to facilitate tumescence in burn eschar and donor sites. J Burn Care Res 2009; 30:906.</a></li><li><a class="nounderline abstract_t">Bussolin L, Busoni P, Giorgi L, et al. Tumescent local anesthesia for the surgical treatment of burns and postburn sequelae in pediatric patients. Anesthesiology 2003; 99:1371.</a></li><li><a class="nounderline abstract_t">Fujita K, Mishima Y, Iwasawa M, Matsuo K. The practical procedure of tumescent technique in burn surgery for excision of burn eschar. J Burn Care Res 2008; 29:924.</a></li><li><a class="nounderline abstract_t">O'Mara MS, Hayetian F, Slater H, et al. Results of a protocol of transfusion threshold and surgical technique on transfusion requirements in burn patients. Burns 2005; 31:558.</a></li><li><a class="nounderline abstract_t">Robertson RD, Bond P, Wallace B, et al. The tumescent technique to significantly reduce blood loss during burn surgery. Burns 2001; 27:835.</a></li><li><a class="nounderline abstract_t">Tapking C, Hundeshagen G, Kirchner M, et al. Tranexamic acid reduced blood transfusions in acute burn surgery: A retrospective case-controlled trial. Burns 2022; 48:522.</a></li><li><a class="nounderline abstract_t">Domínguez A, Alsina E, Landín L, et al. Transfusion requirements in burn patients undergoing primary wound excision: effect of tranexamic acid. Minerva Anestesiol 2017; 83:353.</a></li><li><a class="nounderline abstract_t">Walsh K, Nikkhah D, Dheansa B. What is the evidence for tranexamic acid in burns? Burns 2014; 40:1055.</a></li><li><a class="nounderline abstract_t">K S A, Kumar P, Subair M, Sharma RK. Effect of single dose intravenous tranexamic acid on blood loss in tangential excision of burn wounds - A double blind randomised controlled trial. Burns 2022; 48:1311.</a></li><li><a class="nounderline abstract_t">Housewright CD, Lenis A, Butler DF. Oscillating electric dermatome use for harvesting split-thickness skin grafts. Dermatol Surg 2010; 36:1179.</a></li><li><a class="nounderline abstract_t">Burget GC, Menick FJ. The subunit principle in nasal reconstruction. Plast Reconstr Surg 1985; 76:239.</a></li><li><a class="nounderline abstract_t">GONZALEZ-ULLOA M, CASTILLO A, STEVENS E, et al. Preliminary study of the total restoration of the facial skin. Plast Reconstr Surg (1946) 1954; 13:151.</a></li><li><a class="nounderline abstract_t">Rode H, Martinez R, Potgieter D, et al. Experience and outcomes of micrografting for major paediatric burns. Burns 2017; 43:1103.</a></li><li><a class="nounderline abstract_t">Papp A, Härmä M. A collagen based dermal substitute and the modified Meek technique in extensive burns. Report of three cases. Burns 2003; 29:167.</a></li><li><a class="nounderline abstract_t">Menon S, Li Z, Harvey JG, Holland AJ. The use of the Meek technique in conjunction with cultured epithelial autograft in the management of major paediatric burns. Burns 2013; 39:674.</a></li><li><a class="nounderline abstract_t">Chong SJ, Choke A, Tan BK. Technical tips to enhance micrografting results in burn surgery. Burns 2017; 43:983.</a></li><li><a class="nounderline abstract_t">Currie LJ, Sharpe JR, Martin R. The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review. Plast Reconstr Surg 2001; 108:1713.</a></li><li><a class="nounderline abstract_t">Sterling JB, Skouge JW. Surgical glue to secure small split-thickness skin grafts: a cost-effective and time-saving technique. Dermatol Surg 2008; 34:246.</a></li><li><a class="nounderline abstract_t">Chen TM, Tsai JC, Burnouf T. A novel technique combining platelet gel, skin graft, and fibrin glue for healing recalcitrant lower extremity ulcers. Dermatol Surg 2010; 36:453.</a></li><li><a class="nounderline abstract_t">Reddy KS, Chittoria RK, Babu P, et al. Effectiveness of Fibrin Glue in Adherence of Skin Graft. J Cutan Aesthet Surg 2017; 10:72.</a></li><li><a class="nounderline abstract_t">Foster K, Greenhalgh D, Gamelli RL, et al. Efficacy and safety of a fibrin sealant for adherence of autologous skin grafts to burn wounds: results of a phase 3 clinical study. J Burn Care Res 2008; 29:293.</a></li><li><a class="nounderline abstract_t">Gibran N, Luterman A, Herndon D, et al. Comparison of fibrin sealant and staples for attaching split-thickness autologous sheet grafts in patients with deep partial- or full-thickness burn wounds: a phase 1/2 clinical study. J Burn Care Res 2007; 28:401.</a></li><li><a class="nounderline abstract_t">Miller R, Wormald JCR, Wade RG, Collins DP. Systematic review of fibrin glue in burn wound reconstruction. Br J Surg 2019; 106:165.</a></li><li><a class="nounderline abstract_t">Foster K. The use of fibrin sealant in burn operations. Surgery 2007; 142:S50.</a></li><li><a class="nounderline abstract_t">Brölmann FE, Eskes AM, Goslings JC, et al. Randomized clinical trial of donor-site wound dressings after split-skin grafting. Br J Surg 2013; 100:619.</a></li><li><a class="nounderline abstract_t">Cihantimur B, Kahveci R, Ozcan M. Comparing Kaltostat with Jelonet in the treatment of split-thickness skin graft donor sites. Eur J Plastic Surg 1997; 20:260.</a></li><li><a class="nounderline abstract_t">Terrill PJ, Goh RC, Bailey MJ. Split-thickness skin graft donor sites: a comparative study of two absorbent dressings. J Wound Care 2007; 16:433.</a></li><li><a class="nounderline abstract_t">Schwarze H, Küntscher M, Uhlig C, et al. Suprathel, a new skin substitute, in the management of donor sites of split-thickness skin grafts: results of a clinical study. Burns 2007; 33:850.</a></li><li><a class="nounderline abstract_t">Voineskos SH, Ayeni OA, McKnight L, Thoma A. Systematic review of skin graft donor-site dressings. Plast Reconstr Surg 2009; 124:298.</a></li><li><a class="nounderline abstract_t">Dornseifer U, Lonic D, Gerstung TI, et al. The ideal split-thickness skin graft donor-site dressing: a clinical comparative trial of a modified polyurethane dressing and aquacel. Plast Reconstr Surg 2011; 128:918.</a></li><li><a class="nounderline abstract_t">Malpass KG, Snelling CF, Tron V. Comparison of donor-site healing under Xeroform and Jelonet dressings: unexpected findings. Plast Reconstr Surg 2003; 112:430.</a></li><li><a class="nounderline abstract_t">Ghosh K, Ponniah AJ, Jones I, et al. The ideal donor-site dressing: are we clear yet? Plast Reconstr Surg 2010; 126:279e.</a></li><li><a class="nounderline abstract_t">Kazanavičius M, Cepas A, Kolaityte V, et al. The use of modern dressings in managing split-thickness skin graft donor sites: a single-centre randomised controlled trial. J Wound Care 2017; 26:281.</a></li><li><a class="nounderline abstract_t">Eskes AM, Brölmann FE, Gerbens LA, et al. Which dressing do donor site wounds need?: study protocol for a randomized controlled trial. Trials 2011; 12:229.</a></li><li><a class="nounderline abstract_t">Fatah MF, Ward CM. The morbidity of split-skin graft donor sites in the elderly: the case for mesh-grafting the donor site. Br J Plast Surg 1984; 37:184.</a></li><li><a class="nounderline abstract_t">Ottomann C, Hartmann B, Tyler J, et al. Prospective randomized trial of accelerated re-epithelization of skin graft donor sites using extracorporeal shock wave therapy. J Am Coll Surg 2010; 211:361.</a></li><li><a class="nounderline abstract_t">Navarro FA, Stoner ML, Park CS, et al. Sprayed keratinocyte suspensions accelerate epidermal coverage in a porcine microwound model. J Burn Care Rehabil 2000; 21:513.</a></li><li><a class="nounderline abstract_t">Gravante G, Di Fede MC, Araco A, et al. A randomized trial comparing ReCell system of epidermal cells delivery versus classic skin grafts for the treatment of deep partial thickness burns. Burns 2007; 33:966.</a></li><li><a class="nounderline abstract_t">Bian Y, Sun C, Zhang X, et al. Wound-healing improvement by resurfacing split-thickness skin donor sites with thin split-thickness grafting. Burns 2016; 42:123.</a></li><li><a class="nounderline abstract_t">Goverman J, Kraft CT, Fagan S, Levi B. Back Grafting the Split-Thickness Skin Graft Donor Site. J Burn Care Res 2017; 38:e443.</a></li><li><a class="nounderline abstract_t">Domaszewska-Szostek AP, Krzyżanowska MO, Czarnecka AM, Siemionow M. Local Treatment of Burns with Cell-Based Therapies Tested in Clinical Studies. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Holmes Iv JH, Molnar JA, Carter JE, et al. A Comparative Study of the ReCell® Device and Autologous Spit-Thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries. J Burn Care Res 2018; 39:694.</a></li><li><a class="nounderline abstract_t">Iwuagwu FC, Wilson D, Bailie F. The use of skin grafts in postburn contracture release: a 10-year review. Plast Reconstr Surg 1999; 103:1198.</a></li><li><a class="nounderline abstract_t">Holavanahalli RK, Helm PA, Kowalske KJ. Long-term outcomes in patients surviving large burns: the skin. J Burn Care Res 2010; 31:631.</a></li><li><a class="nounderline abstract_t">Adams DC, Ramsey ML. Grafts in dermatologic surgery: review and update on full- and split-thickness skin grafts, free cartilage grafts, and composite grafts. Dermatol Surg 2005; 31:1055.</a></li><li><a class="nounderline abstract_t">Chakravorty RC, Sosnowski KM. Autologous fibrin glue in full-thickness skin grafting. Ann Plast Surg 1989; 23:488.</a></li><li><a class="nounderline abstract_t">Chang KP, Tsai CC, Lin TM, et al. An alternative dressing for skin graft immobilization: negative pressure dressing. Burns 2001; 27:839.</a></li><li><a class="nounderline abstract_t">Moisidis E, Heath T, Boorer C, et al. A prospective, blinded, randomized, controlled clinical trial of topical negative pressure use in skin grafting. Plast Reconstr Surg 2004; 114:917.</a></li><li><a class="nounderline abstract_t">Scherer LA, Shiver S, Chang M, et al. The vacuum assisted closure device: a method of securing skin grafts and improving graft survival. Arch Surg 2002; 137:930.</a></li><li><a class="nounderline abstract_t">Seymour FK, Giele HP. Tie-overs under pressure. Br J Plast Surg 2003; 56:494.</a></li><li><a class="nounderline abstract_t">Edgar D, Brereton M. Rehabilitation after burn injury. BMJ 2004; 329:343.</a></li><li class="breakAll">Serghiou MA, Farmer SA. A practical approach to acure burn rehabilitation. In: Principles and Practice of Burn Surgery, Barret Nerin JP, Herndon DN, Dekker M (Eds), CRC Press, New York 2005. p.317.</li><li><a class="nounderline abstract_t">Lagziel T, Ramos M, Klifto KM, et al. Complications With Time-to-Ambulation Following Skin Grafting for Burn Patients: A Meta-Analysis and Systematic Review. Cureus 2021; 13:e17214.</a></li></ol></div><div id="topicVersionRevision">Topic 15118 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14740962" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Skin grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18084131" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Useful tips for successful skin grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18226455" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The mechanism of skin graft contraction: an update on current research and potential future therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19250899" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Resurfacing of colour-mismatched free flaps on the face with split-thickness skin grafts from the scalp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11226657" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Recontruction of facial defects and burn scars using large size freehand full-thickness skin graft from lateral thoracic region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Use of lower abdominal full-thickness skin grafts for coverage of large skin defects</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9460579" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Skin grafting. From here to there.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19692924" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A simple technique to facilitate tumescence in burn eschar and donor sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14639151" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tumescent local anesthesia for the surgical treatment of burns and postburn sequelae in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18849848" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The practical procedure of tumescent technique in burn surgery for excision of burn eschar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15955634" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Results of a protocol of transfusion threshold and surgical technique on transfusion requirements in burn patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11718986" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The tumescent technique to significantly reduce blood loss during burn surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35339324" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Tranexamic acid reduced blood transfusions in acute burn surgery: A retrospective case-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27827518" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Transfusion requirements in burn patients undergoing primary wound excision: effect of tranexamic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24836822" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : What is the evidence for tranexamic acid in burns?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34952736" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of single dose intravenous tranexamic acid on blood loss in tangential excision of burn wounds - A double blind randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20533934" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Oscillating electric dermatome use for harvesting split-thickness skin grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4023097" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The subunit principle in nasal reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13145324" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Preliminary study of the total restoration of the facial skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28318749" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Experience and outcomes of micrografting for major paediatric burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12615465" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A collagen based dermal substitute and the modified Meek technique in extensive burns. Report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23026638" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The use of the Meek technique in conjunction with cultured epithelial autograft in the management of major paediatric burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28442165" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Technical tips to enhance micrografting results in burn surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11711954" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18093189" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Surgical glue to secure small split-thickness skin grafts: a cost-effective and time-saving technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20187900" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A novel technique combining platelet gel, skin graft, and fibrin glue for healing recalcitrant lower extremity ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28852291" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effectiveness of Fibrin Glue in Adherence of Skin Graft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18354285" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and safety of a fibrin sealant for adherence of autologous skin grafts to burn wounds: results of a phase 3 clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17438504" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparison of fibrin sealant and staples for attaching split-thickness autologous sheet grafts in patients with deep partial- or full-thickness burn wounds: a phase 1/2 clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30724361" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Systematic review of fibrin glue in burn wound reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18019939" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The use of fibrin sealant in burn operations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460253" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized clinical trial of donor-site wound dressings after split-skin grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comparing Kaltostat with Jelonet in the treatment of split-thickness skin graft donor sites</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18065019" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Split-thickness skin graft donor sites: a comparative study of two absorbent dressings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17493762" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Suprathel, a new skin substitute, in the management of donor sites of split-thickness skin grafts: results of a clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19568092" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Systematic review of skin graft donor-site dressings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21681125" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The ideal split-thickness skin graft donor-site dressing: a clinical comparative trial of a modified polyurethane dressing and aquacel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12900600" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of donor-site healing under Xeroform and Jelonet dressings: unexpected findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21042095" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The ideal donor-site dressing: are we clear yet?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28598760" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The use of modern dressings in managing split-thickness skin graft donor sites: a single-centre randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21999705" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Which dressing do donor site wounds need?: study protocol for a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6370369" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The morbidity of split-skin graft donor sites in the elderly: the case for mesh-grafting the donor site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20800193" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prospective randomized trial of accelerated re-epithelization of skin graft donor sites using extracorporeal shock wave therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11194804" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Sprayed keratinocyte suspensions accelerate epidermal coverage in a porcine microwound model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17904748" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A randomized trial comparing ReCell system of epidermal cells delivery versus classic skin grafts for the treatment of deep partial thickness burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26615713" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Wound-healing improvement by resurfacing split-thickness skin donor sites with thin split-thickness grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27003740" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Back Grafting the Split-Thickness Skin Graft Donor Site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33494318" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Local Treatment of Burns with Cell-Based Therapies Tested in Clinical Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29800234" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A Comparative Study of the ReCell®Device and Autologous Spit-Thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10088507" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The use of skin grafts in postburn contracture release: a 10-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20523226" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Long-term outcomes in patients surviving large burns: the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16042930" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Grafts in dermatologic surgery: review and update on full- and split-thickness skin grafts, free cartilage grafts, and composite grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2624391" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Autologous fibrin glue in full-thickness skin grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11718987" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : An alternative dressing for skin graft immobilization: negative pressure dressing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15468399" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A prospective, blinded, randomized, controlled clinical trial of topical negative pressure use in skin grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12146992" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The vacuum assisted closure device: a method of securing skin grafts and improving graft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12890464" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Tie-overs under pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15297346" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Rehabilitation after burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15297346" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Rehabilitation after burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34540441" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Complications With Time-to-Ambulation Following Skin Grafting for Burn Patients: A Meta-Analysis and Systematic Review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
